Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences reports $353 million full-year 2025 net loss, up from $283 million

Negative Impact 4 of 5 earnings Written later

Arcus Biosciences reported fourth-quarter and full-year 2025 results on February 25, 2026. Revenue declined and the net loss widened for both periods, and the company gave 2026 GAAP revenue guidance of $45 million to $55 million. Arcus and Gilead are winding down the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies, and the company expects R&D expenses to decrease meaningfully in 2026.

Key points

  • Full-year 2025 revenue was $247 million, down from $258 million in 2024; net loss was $353 million, or $3.29 per share, versus $283 million, or $3.14 per share in 2024
  • Fourth-quarter 2025 revenue was $33 million, down from $36 million; net loss was $106 million, compared with $94 million a year earlier
  • Company expects GAAP revenue of $45 million to $55 million for full-year 2026
  • Cash, cash equivalents and marketable securities were $1.0 billion at December 31, 2025, versus $992 million a year earlier, with funding expected until at least the second half of 2028

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECFeb 25, 2026, 4:08 PM ET
Accession number0001724521-26-000007

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.